Evaluation of the Depth and Duration of Anesthesia From Heated Lidocaine/Tetracaine (Synera®) Patches Compared With 5% Lidocaine (Lidoderm®) Patches Applied to Healthy Adult Volunteers

NCT ID: NCT01688518

Last Updated: 2013-01-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-09-30
• Study Completion Date: 2012-11-30

Brief Summary

This will be a randomized, single-blind, active-controlled, two-period crossover study in adult volunteers to compare the duration and depth of anesthesia between Synera® and Lidoderm® patches when applied for 30 minutes and 4 hours. The study will include a Screening Visit, two Treatment Periods, and a Follow-Up Phone Contact.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

Synera® for 30min & Lidoderm® for 4 hours

Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.

Group Type: ACTIVE_COMPARATOR

Heated Lidocaine/Tetracaine Patch

Intervention Type: DRUG

5% Lidocaine Patch

Intervention Type: DRUG

Lidoderm® for 30min & Synera® for 4 hours

Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.

Group Type: ACTIVE_COMPARATOR

Heated Lidocaine/Tetracaine Patch

Intervention Type: DRUG

5% Lidocaine Patch

Intervention Type: DRUG

Interventions

Heated Lidocaine/Tetracaine Patch

Intervention Type: DRUG

5% Lidocaine Patch

Intervention Type: DRUG

Other Intervention Names

Synera® Patch; Lidoderm® Patch

Eligibility Criteria

Inclusion Criteria

1. Subject is male or female 18-60 years of age, inclusive.

2. Subject is judged by the Investigator to be in generally good health at screening based upon the results of a medical history, physical examination, clinical laboratory profile, and 12-lead electrocardiogram (ECG).

3. Subject is willing to refrain from using any local topical preparations on the volar aspect of the forearms for 24 hours prior to each site visit.

4. Subject has normal, intact skin bilaterally at the antecubital area.

5. If female, must be of non-childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or must be using adequate contraception (practicing one of the following methods of birth control):

• Total abstinence from sexual intercourse (minimum of one complete menstrual cycle before study entry),
• A vasectomized partner,
• Contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior to test product administration,
• Intrauterine device (IUD), or
• Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream).

6. If female, must have a negative urine pregnancy test at Screening and at check-in of each Treatment Period.

7. Subject is willing to be blindfolded during the study and agrees to abide by all study restrictions and comply with all study procedures.

8. Able to fluently speak and understand English and be able to provide meaningful written informed consent for the study.

Exclusion:

1. Subject has clinically significant ECG abnormalities at screening.

2. Subject is currently receiving class I, II, or III anti-arrhythmic agents.

3. Subject has used over-the-counter (OTC) or prescription analgesics within 24 hours prior to either study period.

4. Subject has a known allergy or history of significant adverse reaction to any component of the treatment or related compounds.

5. Subject has a history of or active use or abuse of illicit drug substance or alcohol abuse.

6. Subject has a positive urine test result for drugs of abuse or a positive ethanol breath test at the Screening Visit or check-in to Treatment Visit 1.

7. Subject has active dermatological disease of any origin that may interfere with the ability to participate.

8. Subject has denuded or broken skin on either forearm.

9. Subject has a history of unstable peripheral/vascular disease and/or hypertensive vascular disease.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Nuvo Research Inc.

INDUSTRY

Sponsor Role: collaborator

CRI Lifetree

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Miroslav Backonja, MD

Role: PRINCIPAL_INVESTIGATOR

CRI Lifetree

Locations

Lifetree Clinical Research

Salt Lake City, Utah, United States

Countries

United States

Other Identifiers

LCR-07-01-101

Identifier Type: -

Identifier Source: org_study_id